Xu Qingqing, Li Mo, Qin Shengying, Li Yaojing, Ning Ailing, Fu Yingmei, Wang Dongxiang, Zeng Duan, Li Huafang, Yu Wenjuan, Yu Shunying
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.
Front Pharmacol. 2020 Jan 31;11:7. doi: 10.3389/fphar.2020.00007. eCollection 2020.
There are great individual differences in the drug responses; however, there are few prognostic drug response biomarkers available. is one of the more extensively examined schizophrenia candidate genes. The purpose of this study was to determine whether can affect antipsychotics response in the Chinese population. This may lead to the discovery of relevant novel drug response markers.
The unrelated 260 Chinese Han inpatients with schizophrenia were enrolled in the present study. The enrolled subjects have been prescribed antipsychotic medication during the study. A total of 15 SNPs of were genotyped by MassARRAY platform. The association of the gene with therapeutic response to antipsychotics was analyzed based on sex and age at onset.
Two novel SNPs of were found to be associated with antipsychotic treatment response (rs155333, p = 0.010 and rs6465938, p = 0.049) at nominal significance threshold, but not after multiple correction. Our study also revealed highly significant association of a haplotype consisting of three SNPs (rs362814-rs362626-rs2237628) with antipsychotic treatment response. Even after permutation, the -value indicated significant association (rs362814-rs362626-rs2237628: ACT, χ = 6.353, = 0.0117, permuted = 0.04). Furthermore, a novel SNP, rs2535764, was found to be associated with antipsychotic response under overdominant genetic model at a marginal significant level of 0.046 (C/T vs. C/C + T/T: = 0.046, AIC = 314.7, BIC = 321.6).
Our data indicated that can affect antipsychotic treatment outcomes in the Chinese population. SNPs of could be used as predictive biomarkers for future personalized medicine of antipsychotic drug treatment. However, none of the three novel SNPs (rs155333, rs6465938, and rs2535764) remained significant after Bonferroni correction. Therefore, validation is needed in larger pharmacogenetic studies.
药物反应存在很大的个体差异;然而,可用的预后药物反应生物标志物很少。[基因名称]是研究较为广泛的精神分裂症候选基因之一。本研究的目的是确定[基因名称]是否会影响中国人群对抗精神病药物的反应。这可能会导致发现相关的新型药物反应标志物。
本研究纳入了260名无亲缘关系的中国汉族精神分裂症住院患者。纳入的受试者在研究期间已接受抗精神病药物治疗。通过MassARRAY平台对[基因名称]的15个单核苷酸多态性(SNP)进行基因分型。基于性别和发病年龄分析[基因名称]基因与抗精神病药物治疗反应的相关性。
在名义显著性阈值下,发现[基因名称]的两个新型SNP与抗精神病药物治疗反应相关(rs155333,p = 0.0